NextFlo

NextFlo is a fixed-dose combination therapy delivered via a proprietary dry powder inhaler (DPI), primarily indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It consists of fluticasone propionate, a synthetic corticosteroid, and salmeterol xinafoate, a long-acting beta2-adrenergic agonist (LABA). Fluticasone propionate reduces airway inflammation by binding to glucocorticoid receptors, thereby inhibiting the production of multiple inflammatory cytokines and mediators. Salmeterol induces bronchodilation by selectively stimulating beta-2 adrenergic receptors on bronchial smooth muscle, leading to increased intracellular cyclic AMP and subsequent muscle relaxation. The NextFlo device itself is a multi-dose dry powder inhaler designed to provide consistent and accurate dose delivery across a wide range of patient inspiratory flow rates, ensuring effective deposition of the medication in the lungs.

Brand names

NextFlo

Other names

fluticasone propionate and salmeterol inhalation powder